M
MGX
Metagenomi Therapeutics, Inc
1.020
+0.020+2.00%After Hours: 1.050 +0.030 +2.94%19:30 10/12 EDT
OPEN/PREV CLOSE1.020/1.020
TODAY RANGE0.9600-1.030
VOL47.95K
MARKET CAP36.27M
52 WEEK RANGE0.9600-3.950
AVG VOL (3M)151.84K
% TURNOVER0.13%
TURNOVER--
P/E (TTM)-0.3855
% RANGE6.86%
EPS(TTM)-2.4905
P/E(FORWARD)-0.3851
P/B0.3222
BVPS2.980
DIVIDEND--
P/S1.433
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP29.27M
SHARES OUTSTANDING37.78M
NEXT EARNINGS11/09-11/13
FREE FLOAT30.48M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·09/22 10:28
Metagenomi updates hemophilia A gene editing program
TipRanks·08/18 04:15
J.P. Morgan Keeps Their Hold Rating on Metagenomi, Inc. (MGX)
Simply Wall St·08/13 12:41
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Simply Wall St·08/12 11:55
These Analysts Think Metagenomi Therapeutics, Inc.'s (NASDAQ:MGX) Sales Are Under Threat
Dow Jones·08/11 13:19
Metagenomi Therapeutics Price Target Cut to $7.00/Share From $9.00 by Wells Fargo
Dow Jones·08/11 13:19
Metagenomi Therapeutics Is Maintained at Overweight by Wells Fargo
TipRanks·08/11 11:11
Metagenomi price target lowered to $7 from $9 at Wells Fargo
TipRanks·08/11 10:57
Metagenomi, Inc. (MGX) Receives a Buy from Wells Fargo
Dow Jones·08/10 20:05
Press Release: Metagenomi Therapeutics Reports -2-
NASDAQ·08/04 21:15
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
Dow Jones·07/07 11:08
Metagenomi Price Target Cut to $5.00/Share From $7.00 by Chardan Capital
Same Industry
Name/Symbol
Change%
Price